BIOTECHNOLOGY VALUE FUND L P 4

What Happened

• BVF Partners L.P. (part of a group of reporting entities and tied to a director on Kymera’s board) was reported as receiving an award of 6,068 derivative shares in Kymera Therapeutics (KYMR) on 2026-06-24. The transaction is reported as an award/grant (code A) with an acquisition price of $0.00, so no cash was paid on filing. The filing indicates these are derivative securities (e.g., options/awards) rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-24; Form 4 filed 2026-06-25 (timely filing).
• Transaction type/code: Award/Grant (A); derivative securities acquired at $0.00.
• Amount: 6,068 shares acquired; reported value $0 on the Form 4.
• Shares owned after transaction: not specified in the provided filing extract.
• Notable footnotes: the Form 4 is filed jointly by several BVF entities and Mark Lampert (Section 13(d) group) and disclaims direct beneficial ownership except to the extent of pecuniary interest (see footnotes). A board member, Gorjan Hrustanovic, is involved and has agreed to transfer any economic benefit from the shares to Partners. Vesting/derivative details are referenced in the footnotes (some awards reference vesting schedules; the filing also includes a note that certain shares subject to an option have fully vested).
• Transaction code meaning: A = Award/Grant. This is a derivative award, not an open-market buy or sale.

Context

• This is an institutional/investor-group award tied to a board member’s arrangement with BVF, not a direct cash purchase or sale by an individual executive. For retail investors, awards at $0 often reflect compensation or investment arrangements and do not necessarily signal immediate buying conviction. The derivative nature means cash was not exchanged at filing; check future filings for exercises or sales.